---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-002841"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:26:47.950456+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences reports Q4 net loss $3.3M, cash $4.9M; advances TAEUS regulatory submission

## Summary
- Net loss Q4 2022 $3.3M ($1.04/share) vs Q4 2021 $3.1M ($1.48/share); FY2022 net loss $13.2M ($4.56/share).
- Cash and equivalents $4.9M at Dec 31, 2022; company notes exposure to SVB failure but deposits spread across multiple banks.
- Over 100 TAEUS scans at clinical sites in 2022; interactive guidance tool deployed to improve operator performance.
- Plans to submit De Novo request to FDA for TAEUS liver device; renewed GE HealthCare collaboration through Dec 2024.
- Operating expenses up to $3.3M in Q4 and $13.2M in FY, driven by product development and European commercialization.

## SEC filing metadata
- accession: 0001654954-23-002841
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495423002841/0001654954-23-002841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495423002841/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-002841
- JSON: https://secwatch.observer/filing/0001654954-23-002841.json
- Plain text: https://secwatch.observer/filing/0001654954-23-002841.txt

## Key facts
- Earnings Releases
  ENDRA Life Sciences Inc. reported the fourth quarter of 2022 results: net income Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share, EPS $1.04 per share.
  - Period: the fourth quarter of 2022
  - Net income: Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share
  - EPS: $1.04 per share
  - Result: reported results
  source text: Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share, compared with a net loss of $3.1 million, or $1.48 per share, in the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495423002841/0001654954-23-002841-index.htm
- Earnings Releases
  ENDRA Life Sciences Inc. reported the year ended December 31, 2022 results: net income Net loss in 2022 was $13.2 million, or $4.56 per share, EPS $4.56 per share.
  - Period: the year ended December 31, 2022
  - Net income: Net loss in 2022 was $13.2 million, or $4.56 per share
  - EPS: $4.56 per share
  - Result: reported results
  source text: Net loss in 2022 was $13.2 million, or $4.56 per share, compared with a net loss of $11.2 million, or $5.55 per share, in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495423002841/0001654954-23-002841-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.